Uploaded November 2025 | Updated September 2026, 3 days ago

---

Can an oral medication really match the heart-protective power of injectable GLP-1 therapies?
In this EASD 2025 interview, Dr Matthew Cavender (University of North Carolina) breaks down the landmark SOUL trial, which evaluated the cardiovascular outcomes of oral semaglutide in over 8,000 people with type 2 diabetes.

The findings show a 14% reduction in cardiovascular death, heart attack, or stroke, proving that oral GLP-1 therapy can deliver the same powerful benefits as injectable forms and could make life-changing treatment more accessible to patients worldwide. Dr Cavender also explores what the results mean for clinicians, both diabetologists and cardiologists, and highlights how a collaborative, team-based approach to care can maximise the impact of these therapies.

Watch the full discussion to understand why the SOUL trial marks a major step forward in diabetes and cardiovascular care.

#easd2025 #soul #trial #type2diabetes #glp1 #cardiovascularhealth #diabetestreatment #endocrinology #cardiology #diabetesresearch #metabolichealth #clinicaltrials #precisionmedicine #medicalresearch